Gene therapy with hematopoietic stem cells: The diseased bone marrow's point of view

Stem Cells and Development

Volumn 26, Issue 2, 2017, Pages 71-76

  Cavazzana, Marina ^a,b,c,d   Ribeil, Jean Antoine ^a   Lagresle Peyrou, Chantal ^b,c,d   André Schmutz, Isabelle ^b,c,d  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c University of Sorbonne Paris la Cité   (France)

^d INSERM   (France)

Author keywords

bone marrow; gene therapy; HSC

Indexed keywords

BONE MARROW DISEASE; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL (TOPIC); GENE THERAPY; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHY; HUMAN; PRIORITY JOURNAL; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; WISKOTT ALDRICH SYNDROME; ANIMAL; BONE MARROW; BONE MARROW DISEASES; CYTOLOGY; PATHOLOGY;

ANIMALS; BONE MARROW; BONE MARROW DISEASES; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS;

EID: 85009740686     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2016.0230     Document Type: Review

References (59)

1. Hacein-Bey-Abina S, J Hauer, A Lim, C Picard, GP Wang, CC Berry, C Martinache, F Rieux-Laucat, S Latour, et al. (2003). Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363:355-364.
2. Hacein-Bey-Abina S, A Garrigue, GP Wang, J Soulier, A Lim, E Morillon, E Clappier, L Caccavelli, E Delabesse, et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118:3132-3142.
3. Ott MG, M Schmidt, K Schwarzwaelder, S Stein, U Siler, U Koehl, H Glimm, K Kuhlcke, A Schilz, et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12:401-409.
4. Stein S, MG Ott, S Schultze-Strasser, A Jauch, B Burwinkel, A Kinner, M Schmidt, A Kramer, J Schwable, et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16:198-204.
5. Wu X, Y Li, B Crise and SM Burgess. (2003). Transcription start regions in the human genome are favored targets for MLV integration. Science 300:1749-1751.
6. Sessa M, L Lorioli, F Fumagalli, S Acquati, D Redaelli, C Baldoli, S Canale, ID Lopez, F Morena, et al. (2016). Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a nonrandomised, open-label, phase 1/2 trial. Lancet 388:476-487.
7. Ghosh S, AJ Thrasher and HB Gaspar. (2015). Gene therapy for monogenic disorders of the bone marrow. Br J Haematol 171:155-170.
8. Cartier N, S Hacein-Bey-Abina, CC Bartholomae, G Veres, M Schmidt, I Kutschera, M Vidaud, U Abel, L Dal-Cortivo, et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326:818-823.
9. Bernardo ME and A Aiuti. (2016). The role of conditioning in hematopoietic stem cell gene therapy. Hum Gene Ther 27;10:741-748.
10. Fischer A, LD Notarangelo, B Neven, M Cavazzana and JM Puck. (2015). Severe combined immunodeficiencies and related disorders. Nat Rev Dis Primers 1:15061.
11. van der Burg M and AR Gennery. (2011). Educational paper. The expanding clinical and immunological spectrum of severe combined immunodeficiency. Eur J Pediatr 170: 561-571.
12. Buckley RH. (2002). Primary immunodeficiency diseases: dissectors of the immune system. Immunol Rev 185:206-219.
13. Wiekmeijer AS, K Pike-Overzet, IJspeert H, MH Brugman, IL Wolvers-Tettero, AC Lankester, RG Bredius, JJ van Dongen, WE Fibbe, et al. (2015). Identification of checkpoints in human T-cell development using severe combined immunodeficiency stem cells. J Allergy Clin Immunol 137:517-526.e3.
14. Mombaerts P, J Iacomini, RS Johnson, K Herrup, S Tonegawa and VE Papaioannou. (1992). RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869-877.
15. Shinkai Y, G Rathbun, KP Lam, EM Oltz, V Stewart, M Mendelsohn, J Charron, M Datta, F Young, et al. (1992). RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68:855-867.
16. Moshous D, I Callebaut, R de Chasseval, B Corneo, M Cavazzana-Calvo, F Le Deist, I Tezcan, O Sanal, Y Bertrand, et al. (2001). Artemis, a novel DNA double-strand break repair/ V(D)J recombination protein, ismutated in human severe combined immune deficiency. Cell 105:177-186.
17. Touzot F, D Moshous, R Creidy, B Neven, P Frange, G Cros, L Caccavelli, J Blondeau, A Magnani, et al. (2015). Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCIDX1. Blood 125:3563-3569.
18. Gaspar HB, A Aiuti, F Porta, F Candotti, MS Hershfield and LD Notarangelo. (2009). How I treat ADA deficiency. Blood 114:3524-3532.
19. Sokolic R, I Maric, C Kesserwan, E Garabedian, IC Hanson, M Dodds, R Buckley, AC Issekutz, N Kamani, et al. (2011). Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. Blood 118:2688-2694.
20. Gaspar HB. (2012). Gene therapy for ADA-SCID: defining the factors for successful outcome. Blood 120:3628-3629.
21. Cicalese MP, F Ferrua, L Castagnaro, R Pajno, F Barzaghi, S Giannelli, F Dionisio, I Brigida, M Bonopane, et al. (2016). Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood 128:45-54.
22. Holland SM. (2013). Chronic granulomatous disease. Hematol Oncol Clin North Am 27:89-99, viii.
23. Grez M, J Reichenbach, J Schwable, R Seger,MCDinauer and AJ Thrasher. (2011). Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther 19:28-35.
24. Weisser M, UM Demel, S Stein, L Chen-Wichmann, F Touzot, G Santilli, S Sujer, C Brendel, U Siler, et al. (2016). Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions. J Allergy Clin Immunol 138:219-228.e9.
25. Sauce D, M Larsen, S Fastenackels, M Pauchard, H Ait- Mohand, L Schneider, A Guihot, F Boufassa, J Zaunders, et al. (2011). HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 117:5142-5151.
26. Rottman M, C Soudais, G Vogt, L Renia, JF Emile, H Decaluwe, JL Gaillard and JL Casanova. (2008). IFN-gamma mediates the rejection of haematopoietic stem cells in IFNgammaR1- deficient hosts. PLoS Med 5:e26.
27. Bosticardo M, F Marangoni, A Aiuti, A Villa and M Grazia Roncarolo. (2009). Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood 113:6288-6295.
28. Kolhatkar NS, A Brahmandam, CD Thouvenel, S Becker- Herman, HM Jacobs, MA Schwartz, EJ Allenspach, S Khim, AK Panigrahi, et al. (2015). Altered BCR and TLR signals promote enhanced positive selection of autoreactive transitional B cells in Wiskott-Aldrich syndrome. J Exp Med 212:1663-1677.
29. Ochs HD and AJ Thrasher. (2006). The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 117:725-738;quiz 739.
30. Westerberg L, G Greicius, SB Snapper, P Aspenstrom and E Severinson. (2001). Cdc42, Rac1, and the Wiskott- Aldrich syndrome protein are involved in the cytoskeletal regulation of B lymphocytes. Blood 98:1086-1094.
31. Burns S, AJ Thrasher, MP Blundell, L Machesky and GE Jones. (2001). Configuration of human dendritic cell cytoskeleton by Rho GTPases, the WAS protein, and differentiation. Blood 98:1142-1149.
32. Malinova D, M Fritzsche, CR Nowosad, H Armer, PM Munro, MP Blundell, G Charras, P Tolar, G Bouma and AJ Thrasher. (2016). WASp-dependent actin cytoskeleton stability at the dendritic cell immunological synapse is required for extensive, functional T cell contacts. J Leukoc Biol 99:699-710.
33. Haddad E, JL Zugaza, F Louache, N Debili, C Crouin, K Schwarz, A Fischer, W Vainchenker and J Bertoglio. (2001). The interaction between Cdc42 and WASP is required for SDF-1-induced T-lymphocyte chemotaxis. Blood 97:33-38.
34. Zhang J, A Shehabeldin, LA da Cruz, J Butler, AK Somani, M McGavin, I Kozieradzki, AO dos Santos, A Nagy, et al. (1999). Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. J Exp Med 190:1329-1342.
35. Castiello MC, M Bosticardo, F Pala, M Catucci, N Chamberlain, MC van Zelm, GJ Driessen, M Pac, E Bernatowska, et al. (2014). Wiskott-Aldrich Syndrome protein deficiency perturbs the homeostasis of B-cell compartment in humans. J Autoimmun 50:42-50.
36. Lacout C, E Haddad, S Sabri, F Svinarchouk, L Garcon, C Capron, A Foudi, R Mzali, SB Snapper, et al. (2003). A defect in hematopoietic stem cell migration explains the nonrandom X-chromosome inactivation in carriers of Wiskott-Aldrich syndrome. Blood 102:1282-1289.
37. Thrasher AJ, GE Jones, C Kinnon, PM Brickell and DR Katz. (1998). Is Wiskott-Aldrich syndrome a cell trafficking disorder? Immunol Today 19:537-539.
38. Hacein-Bey Abina S, HB Gaspar, J Blondeau, L Caccavelli, S Charrier, K Buckland, C Picard, E Six, N Himoudi, et al. (2015). Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA 313:1550-1563.
39. Frassoni F, F Gualandi, M Podesta, AM Raiola, A Ibatici, G Piaggio, M Sessarego, N Sessarego, M Gobbi, et al. (2008). Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 9:831-839.
40. Heimpel H, K Kellermann, N Neuschwander, J Hogel and K Schwarz. (2010). The morphological diagnosis of congenital dyserythropoietic anemia: results of a quantitative analysis of peripheral blood and bone marrow cells. Haematologica 95:1034-1036.
41. Ribeil JA, JB Arlet, M Dussiot, IC Moura, G Courtois and O Hermine. (2013). Ineffective erythropoiesis in beta - thalassemia. ScientificWorldJournal 2013:394295.
42. Gardenghi S, MF Marongiu, P Ramos, E Guy, L Breda, A Chadburn, Y Liu, N Amariglio, G Rechavi, et al. (2007). Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by downregulation of hepcidin and up-regulation of ferroportin. Blood 109:5027-5035.
43. Karponi G, N Psatha, CW Lederer, JE Adair, F Zervou, N Zogas, M Kleanthous, C Tsatalas, A Anagnostopoulos, et al. (2015). Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. Blood 126:616-619.
44. Boulad F, X Wang, J Qu, C Taylor, L Ferro, G Karponi, S Bartido, P Giardina, G Heller, et al. (2014). Safe mobilization of CD34+ cells in adults with beta-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood 123:1483-1486.
45. Kato GJ. (2016). New insights into sickle cell disease: mechanisms and investigational therapies. Curr Opin Hematol 23:224-232.
46. Grasso JA, AL Sullivan and LW Sullivan. (1975). Ultrastructural studies of the bone marrow in sickle cell anaemia. II. The morphology of erythropoietic cells and their response to deoxygenation in vitro. Br J Haematol 31:381-389.
47. Grasso JA, AL Sullivan and LW Sullivan. (1975). Ultrastructural studies of the bone marrow in sickle cell anaemia. I. The structure of sickled erythrocytes and reticulocytes and their phagocytic destruction. Br J Haematol 31:135-148.
48. Kuypers FA, RA Lewis, M Hua, MA Schott, D Discher, JD Ernst and BH Lubin. (1996). Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V. Blood 87:1179-1187.
49. de Jong K, RK Emerson, J Butler, J Bastacky, N Mohandas and FA Kuypers. (2001). Short survival of phosphatidylserine-exposing red blood cells in murine sickle cell anemia. Blood 98:1577-1584.
50. Walters MC, M Patience, W Leisenring, ZR Rogers, VM Aquino, GR Buchanan, IA Roberts, AM Yeager, L Hsu, et al. (2001). Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 7:665-673.
51. Wu CJ, L Krishnamurti, JL Kutok, M Biernacki, S Rogers, W Zhang, JH Antin and J Ritz. (2005). Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood 106:3639-3645.
52. Wu CJ, EP Hochberg, SA Rogers, JL Kutok, M Biernacki, AF Nascimento, P Marks, K Bridges and J Ritz. (2003). Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Exp Hematol 31:924-933.
53. Abboud M, J Laver and CA Blau. (1998). Granulocytosis causing sickle-cell crisis. Lancet 351:959.
54. Adler BK, DE Salzman, MH Carabasi, WP Vaughan, VV Reddy and JT Prchal. (2001). Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 97:3313-3314.
55. Grigg AP. (2001). Granulocyte colony-stimulating factorinduced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. Blood 97:3998-3999.
56. Kamble RT, M Hamadani and GB Selby. (2006). Increased mean corpuscular volume after autologous hematopoietic stem cell transplantation: incidence and significance. Biol Blood Marrow Transplant 12:111-112.
57. Oevermann L and R Handgretinger. (2012). New strategies for haploidentical transplantation. Pediatr Res 71:418-426.
58. Psatha N, G Karponi and E Yannaki. (2016). Optimizing autologous cell grafts to improve stem cell gene therapy. Exp Hematol 44:528-539.
59. Six EM, D Bonhomme, M Monteiro, K Beldjord, M Jurkowska, C Cordier-Garcia, A Garrigue, L Dal Cortivo, B Rocha, et al. (2007). A human postnatal lymphoid progenitor capable of circulating and seeding the thymus. J Exp Med 204:3085-3093.